Abbott to Acquire Visiogen, Expanding Vision Treatment Portfolio Abbott has announced a definitive agreement to obtain Visiogen, Inc online pharmacy . For $400 million in money, providing the company with a next-era accommodating intraocular zoom lens technology to address presbyopia for cataract individuals. Visiogen, a privately held company based in Irvine, Calif., with European functions in Karlsruhe, Germany, is an ophthalmic medical device company specializing in the development of fresh vision alternatives for sufferers with cataracts. This acquisition demonstrates Abbott’s continued dedication to vision care and our desire to introduce and accelerate technologies that have the ability to create a difference in the lives of thousands of people around the world, said John M.
Long lasting Growth Business sales elevated 24.3 %, driven by strong Established Pharmaceuticals product sales growth, including the contribution from the Solvay Pharmaceuticals and Piramal Healthcare Solutions acquisitions, and International Nutritionals sales growth of 15.8 %. Proprietary Pharmaceuticals sales improved 11.7 %, including strong performance across several major global brands. Innovation-Driven Device Business sales improved 10.7 %, driven by double-digit growth in Vascular and Molecular Diagnostics. Emerging markets sales had been $2.3 billion, 38 up.4 % from the last year, with strong growth across most of Abbott’s operating divisions and including the effect of acquisitions. Abbott is certainly confirming ongoing earnings-per-share assistance for the full-year 2011, reflecting double-digit development over 2010 at the midpoint of the range.